Is Kallyope profitable in 2026?

No. Kallyope is a clinical-stage biotech with zero FDA-approved products as of 2026, so it has no product revenue. It funds operations through venture rounds and grants, the last priced round being a $236M Series D in February 2022 that valued the company at about $1.27B.

Kallyope is privately held, backed by investors including Bill Gates, Mubadala, Alexandria Venture Investments, Illumina Ventures, Lux Capital, Polaris Partners and Two Sigma Ventures, who funded a $236M Series D in February 2022 at a $1.27B post-money valuation. No IPO has occurred as of 2026.

Could AI replace Kallyope's drug discovery work?

Not fully. Kallyope's Klarity platform already uses single-cell sequencing and computational biology for target discovery, but drug approval still requires FDA-regulated Phase 3 clinical trials, which no AI system can substitute. Its lead drug elismetrep entered Phase 3 in mid-2026 with human trial data required through 2027.

Who is Kallyope's biggest competitor?

In migraine, AbbVie's Ubrelvy and Pfizer's Nurtec dominate the CGRP/gepant class; Kallyope's elismetrep, a first-in-class TRPM8 blocker, entered Phase 3 trials in mid-2026 as a non-CGRP alternative, with pivotal data due in 2027 to test against these entrenched drugs.

What is Kallyope's valuation as of 2026?

Secondary-market estimates place Kallyope's valuation between $1.14B and $1.27B as of March 2026, consistent with its 2022 unicorn status. This is unchanged since its $236M Series D closed in February 2022 at a $1.27B post-money valuation, with no new priced round disclosed since.

United States · United States

Kallyope

Clinical-stage biotech targeting gut-brain circuits, lead drug elismetrep in migraine.

Losing its protection

Assessed 29 July 2026 · Evidence as of 29 July 2026

The structural protection is eroding.

On the recordSince 29 July 2026 · Checkable from 2027 · Every call on the record Checkpoint: Phase 3 pivotal readout for elismetrep in migraine

The call

Kallyope's fate hinges on a single 2027 Phase 3 result and whether it can finance the wait without a new round.

Kallyope is a very early-stage drug company working on a new migraine medicine called elismetrep. The company has not sold any approved drugs yet, so its entire worth depends on whether the FDA approves this one medicine in 2027, which is a single bet with no backup plan. The real danger is not competition from other migraine pills like AbbVie's Ubrelvy or Pfizer's Nurtec, but rather whether Kallyope can afford to keep operating and running tests until 2027, since the company has not raised new money publicly since early 2022 and has not announced any big partnership deals. If Kallyope stays silent about money for the next three years, the company could run out of cash before the FDA decides, which would be the true killer.

Why

AI pressure: AI-driven drug discovery labs like Isomorphic Labs and Recursion Pharmaceuticals. AI-native drug discovery shops could design competing migraine or metabolic molecules faster, but none have a rival asset in the clinic yet. Could AI do the core job? Unlikely.

Bigger players: AbbVie (Ubrelvy) and Pfizer (Nurtec), the approved CGRP/gepant migraine drugs. These gepants already treat migraine patients today; elismetrep has no approval yet, so it isn't losing sales, it just hasn't entered the market. Could a giant copy it? No, they are blocked.

What protects it. A patent-protected, first-in-class TRPM8 blocker with positive Phase 2b data gives it a mechanism no marketed migraine drug uses.

What would change this call

Kallyope reports Phase 3 elismetrep migraine data (expected 2027). Shows whether its lead asset actually works, the core bet behind its valuation.
Kallyope announces a new priced round, IPO filing, or big-pharma partnership before 2027. Shows whether it has cash to reach its 2027 pivotal readout.
K-554 Phase 1 single-ascending-dose results appear (expected H2 2026). Early sign of whether its obesity pipeline is advancing on schedule.

Key numbers

$236M Series D raised at $1.27B valuation (2022-02-15)
Positive Phase 2b results in ~450-patient migraine study (2025-12-09)
No new priced round disclosed in over four years (2026-01-07)

Named risks

No disclosed priced financing round since Feb 2022, raising cash runway concerns into 2027 Phase 3 readout. Severity: high
Entire company valuation hinges on binary Phase 3 outcome for elismetrep due 2027. Severity: high
Crowded GLP-1/obesity market dominated by Lilly and Novo Nordisk could limit K-554's commercial window. Severity: medium
Publicly reported headcount and revenue figures conflict widely across trackers, limiting transparency. Severity: medium
No disclosed litigation or regulatory action found, but absence of disclosure limits verification. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
AbbVie (Ubrelvy)	contesting	Elismetrep Phase 3 initiated mid-2026 as non-CGRP migraine alternative
Pfizer (Nurtec, and Biohaven CGRP class)	contesting	Pfizer paid $11.6B for Biohaven's CGRP franchise in 2022, setting migraine market benchmark
Eli Lilly and Novo Nordisk	losing to	K-554 non-incretin obesity peptide only entering Phase 1 mid-2026 vs approved GLP-1 drugs
Sosei Heptares	gaining on	GPCR target discovery partnership since 2022, first target nominated Nov 2023

Questions people ask

Is Kallyope profitable in 2026?: No. Kallyope is a clinical-stage biotech with zero FDA-approved products as of 2026, so it has no product revenue. It funds operations through venture rounds and grants, the last priced round being a $236M Series D in February 2022 that valued the company at about $1.27B.
Who owns Kallyope?: Kallyope is privately held, backed by investors including Bill Gates, Mubadala, Alexandria Venture Investments, Illumina Ventures, Lux Capital, Polaris Partners and Two Sigma Ventures, who funded a $236M Series D in February 2022 at a $1.27B post-money valuation. No IPO has occurred as of 2026.
Could AI replace Kallyope's drug discovery work?: Not fully. Kallyope's Klarity platform already uses single-cell sequencing and computational biology for target discovery, but drug approval still requires FDA-regulated Phase 3 clinical trials, which no AI system can substitute. Its lead drug elismetrep entered Phase 3 in mid-2026 with human trial data required through 2027.
Who is Kallyope's biggest competitor?: In migraine, AbbVie's Ubrelvy and Pfizer's Nurtec dominate the CGRP/gepant class; Kallyope's elismetrep, a first-in-class TRPM8 blocker, entered Phase 3 trials in mid-2026 as a non-CGRP alternative, with pivotal data due in 2027 to test against these entrenched drugs.
What is Kallyope's valuation as of 2026?: Secondary-market estimates place Kallyope's valuation between $1.14B and $1.27B as of March 2026, consistent with its 2022 unicorn status. This is unchanged since its $236M Series D closed in February 2022 at a $1.27B post-money valuation, with no new priced round disclosed since.

Timeline

2026-07-16Phase 3 trials for elismetrep (NCT07645924, NCT07674654) actively recruiting
2026-06-04Phase 2b elismetrep data presented at American Headache Society meeting
2026-04-22Phase 2b elismetrep data presented at American Academy of Neurology meeting
2026-01-07Kallyope announces 2026 priorities: elismetrep Phase 3, K-554 Phase 1
2025-12-09Kallyope announces positive Phase 2b results for elismetrep in migraine
2025-02-27Kallyope drops K-833 metabolism program and GI/celiac pipeline section
2023-11-10Sosei Heptares and Kallyope nominate first GPCR target under 2022 collaboration
2023-05-09Kallyope records an $8.2M grant
2022-02-15Kallyope raises $236M Series D at $1.27B post-money valuation
2018-06-27Kallyope raises $66M Series B financing

Revision history

29 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

American Airlines Group Wayfair Safe Superintelligence Inc.